Retatrutide
An investigational triple-receptor agonist currently in clinical trials; not FDA-approved.
What it is
Retatrutide is an investigational 'triple agonist' — it targets GLP-1, GIP and glucagon receptors. It is not FDA-approved for anything; it is in late-stage clinical trials.
Phase 2 results published in 2023 reported large average weight reductions, which set the internet on fire and put retatrutide vials on gray-market sites long before any regulator has finished judging it. The honest position: promising published data, incomplete safety picture, no approved product — and anything sold as retatrutide today is by definition not a pharmaceutical product.
What researchers have actually studied it for
Obesity and metabolic disease in ongoing phase 2 and phase 3 clinical trials; no approved indication yet.
How it works
Three receptors, one molecule: the GLP-1 and GIP arms work the incretin pathways of its predecessors, while the added glucagon-receptor activity is believed to raise energy expenditure and act on the liver. The glucagon arm is the novel bet — and the source of effects trials are watching closely, including heart-rate increases.
Where it came from
Retatrutide is Eli Lilly's next step past tirzepatide, applying the same engineering lineage to a third receptor. Its phase 2 obesity data, published in the New England Journal of Medicine in 2023, reported average weight reductions around 24% at the top dose over 48 weeks — the largest yet seen for a drug candidate — sending it into a broad phase 3 program.
What the research record actually contains
- Phase 2 obesity trial (NEJM 2023): ~24% average weight reduction at the highest dose over 48 weeks.
- Phase 2 diabetes and fatty-liver readouts with encouraging metabolic signals.
- Phase 3 TRIUMPH program ongoing — the trials that will define approval, dosing and the real safety profile.
- No published long-term safety data; heart-rate effects observed in phase 2 remain under study.
What's known about risks
Interim at best. Phase 2 reported the class GI effects plus dose-related heart-rate increases; the long-term meaning of chronic glucagon-receptor activation is precisely what phase 3 exists to establish. An unfinished safety story is the honest description — and gray-market vials add unverified contents on top of it.
Where it stands legally
No approval anywhere, so no lawful retail channel exists. It cannot be lawfully compounded, prescribed or sold for human use; trial participation is the only legitimate access. 'Research use only' listings are legal posture, not permission.
Worth asking a licensed provider
- 1.If I'm interested in what retatrutide represents, do I qualify for an approved alternative today?
- 2.Is there a legitimate clinical trial I could actually enroll in?
- 3.What would make waiting for approval the wrong call for my situation?